ijms-logo

Journal Browser

Journal Browser

Special Issue "miRNAs in the Era of Personalized Medicine: From Biomarkers to Therapeutics"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Biochemistry".

Deadline for manuscript submissions: closed (30 April 2021).

Special Issue Editors

Dr. Juan Gilabert-Estellés
E-Mail Website
Guest Editor
1. Research Laboratory in Biomarkers in Reproduction, Gynaecology and Obstetrics, Fundación Hospital General Universitario de Valencia, 46014 València, Spain
2. Comprehensive Multidisciplinary Endometriosis Unit, Consorcio Hospital General Universitario de Valencia, Valencia, Spain. Av. Tres Cruces, 2. PC: 46014 Valencia, Spain
3. Department of Paediatrics, Obstetrics and Gynaecology, University of Valencia, Valencia, Spain. Av. Blasco Ibáñez, 15. PC: 46010, Valencia, Spain
Interests: endometriosis; gynecological oncology; laparoscopy; minimally invasive surgery; robotic surgery; biomarkers
Dr. Josep Marí-Alexandre
E-Mail Website
Guest Editor
Research Laboratory in Biomarkers in Reproduction, Gynaecology and Obstetrics, Fundación Hospital General Universitario de Valencia, 46014 València, Spain
Interests: endometriosis; gynecological oncology; miRNAs; epigenomics; biomarkers; translational research
Prof. Dr. Martin Götte
E-Mail Website
Guest Editor
Department of Gynecology and Obstetrics, University of Münster, Münster, Germany
Interests: endometriosis; gynecological oncology; microRNAs; stem cells; proteoglycans; extracellular matrix; inflammation
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Personalized medicine has become a new paradigm for the management of a wide variety of diseases. A decisive factor for its development has been represented by the molecular characterization of tumours, paving the way for the development of risk stratification algorithms, biomarker development and targeted therapies.

miRNAs have attracted a greater interest in the last years as for the characterization of tumour biology. These small non-coding RNAs with regulatory properties have been proven to be deregulated in several pathologies, from benign pathologies as endometriosis or cardiovascular diseases to distinct forms of solid and haematological malignancies. Since a single miRNA might impact in multiple signalling pathways, they might be involved into disease pathophysiology and also might become potential therapeutic targets. Far from the classical miRNA mimic or antimiR approach, new evidences are pointing to targeted DNA methylation of miRNA promoters as a potential therapeutic strategy. Additionally, the discovery of miRNAs in a myriad of human biofluids has paved the way for its implementation as biomarkers of disease.

This Special Issue aims to broad the knowledge about current advances in the field of miRNAs as mechanisms of disease, biomarkers and potential therapeutic targets. 

Dr. Juan Gilabert-Estellés
Dr. Josep Marí-Alexandre
Dr. Martin Götte
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • miRNAs
  • Biomarkers
  • Therapeutics
  • Personalized medicine

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Canonical and Interior Circular RNAs Function as Competing Endogenous RNAs in Psoriatic Skin
by , , and
Int. J. Mol. Sci. 2021, 22(10), 5182; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22105182 (registering DOI) - 13 May 2021
Abstract
(1) Background: Understanding the function of circular RNAs (circRNAs), a class of noncoding RNA, in psoriatic skin can provide important insights into the complex regulation of genes contributing to the pathogenesis of psoriasis. (2) Methods: A novel method was applied to RNA-seq datasets [...] Read more.
(1) Background: Understanding the function of circular RNAs (circRNAs), a class of noncoding RNA, in psoriatic skin can provide important insights into the complex regulation of genes contributing to the pathogenesis of psoriasis. (2) Methods: A novel method was applied to RNA-seq datasets from 93 skin biopsy samples to comprehensively identify circRNAs of all types, i.e., canonical circRNAs from the intron-exon junctions of mRNAs and interior circRNAs (i-circRNAs) from the interior regions of exons, introns, and intergenic regions. Selected circRNAs were experimentally validated by qRT-PCR and Sanger sequencing. CircRNAs with abundant and differential expression were identified and their putative function as competing endogenous RNAs (ceRNAs) was analyzed by an integrated analysis of circRNAs, microRNAs, and mRNAs. (3) Results: With a comprehensive search using no information of splicing signals, we systematically identified 179 highly abundant circRNAs in psoriatic skin. Many of these were reported for the first time and many were differentially expressed in involved versus normal or uninvolved skin. Validation based on three additional RNA-seq datasets confirmed most of the identified circRNAs in psoriatic skin. Experimental analyses confirmed the expression of the well-known circRNA CDR1as, a canonical circRNA, and a novel i-circRNA in psoriasis. We also identified many circRNAs that may act as ceRNAs to regulate the expression of mRNA genes in psoriasis-related signaling pathways in psoriasis. (4) Conclusions: The result of the study suggested that circRNAs are abundant in psoriatic skin, have distinct characteristics, and contribute to psoriatic pathogenesis. Full article
Open AccessArticle
Circulating miRNAs Act as Diagnostic Biomarkers for Bladder Cancer in Urine
Int. J. Mol. Sci. 2021, 22(8), 4278; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22084278 - 20 Apr 2021
Viewed by 293
Abstract
MicroRNAs (miRNAs) can be secreted into body fluids and have thus been reported as a new type of cancer biomarker. This study aimed to determine whether urinary miRNAs act as noninvasive biomarkers for diagnosing bladder cancer. Small RNA profiles from urine were generated [...] Read more.
MicroRNAs (miRNAs) can be secreted into body fluids and have thus been reported as a new type of cancer biomarker. This study aimed to determine whether urinary miRNAs act as noninvasive biomarkers for diagnosing bladder cancer. Small RNA profiles from urine were generated for 10 patients with bladder cancer and 10 healthy controls by using next-generation sequencing. We identified 50 urinary miRNAs that were differentially expressed in bladder cancer compared with controls, comprising 44 upregulated and six downregulated miRNAs. Pathway enrichment analysis revealed that the biological role of these differentially expressed miRNAs might be involved in cancer-associated signaling pathways. Further analysis of the public database revealed that let-7b-5p, miR-149-5p, miR-146a-5p, miR-193a-5p, and miR-423-5p were significantly increased in bladder cancer compared with corresponding adjacent normal tissues. Furthermore, high miR-149-5p and miR-193a-5p expression was significantly correlated with poor overall survival in patients with bladder cancer. The qRT-PCR approach revealed that the expression levels of let-7b-5p, miR-149-5p, miR-146a-5p and miR-423-5p were significantly increased in the urine of patients with bladder cancer compared with those of controls. Although our results indicated that urinary miRNAs are promising biomarkers for diagnosing bladder cancer, this must be validated in larger cohorts in the future. Full article
Show Figures

Figure 1

Open AccessArticle
The Status of EGFR Modulates the Effect of miRNA-200c on ZEB1 Expression and Cell Migration in Glioblastoma Cells
Int. J. Mol. Sci. 2021, 22(1), 368; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22010368 - 31 Dec 2020
Viewed by 489
Abstract
Migration of glioblastoma cells into surrounding tissue is one of the main features that makes this tumor incurable. We evaluated whole-genome miRNA expression profiling associated with different EGFR amplification patterns in 30 cases of primary glioblastoma. From the 64 miRNAs that showed differential [...] Read more.
Migration of glioblastoma cells into surrounding tissue is one of the main features that makes this tumor incurable. We evaluated whole-genome miRNA expression profiling associated with different EGFR amplification patterns in 30 cases of primary glioblastoma. From the 64 miRNAs that showed differential expression between tumors with a high level of EGFR amplification and tumors without EGFR amplification, 40% were related with cell migration, being miR-200c the most differentially expressed between these two groups. We investigated the effect of miR-200c on ZEB1 expression and cell migration in an in vitro transfection model with a miR-200c mimic, a miR-200c inhibitor and siRNA targeting EGFR in three short-term cultures with different levels of EGFR amplification obtained from resected glioblastomas. The cell culture with the highest EGFR amplification level presented the lowest miR-200c expression and the status of EGFR modulated the effect of miR-200c on ZEB1 expression. Silencing EGFR led to miR-200c upregulation and ZEB1 downregulation in transfected cultures, except in the presence of high levels of EGFR. Likewise, miR-200c upregulation decreased ZEB1 expression and inhibited cell migration, especially when EGFR was not amplified. Our results suggest that modulating miR-200c may serve as a novel therapeutic approach for glioblastoma depending on EGFR status. Full article
Show Figures

Figure 1

Back to TopTop